More Women Switch Out Pharmaceuticals For Medical Marijuana

The Fresh Toast

More Women Switch Out Pharmaceuticals For Medical Marijuana. The post More Women Switch Out Pharmaceuticals For Medical Marijuana appeared first on The Fresh Toast. Medical Marijuana News Endometriosis gynecology menopause pharmaceuticals prescription drugs women

Consumers Are Replacing Pharmaceuticals With Medical Marijuana

The Fresh Toast

Consumers Are Replacing Pharmaceuticals With Medical Marijuana In recent years, certain states that have medical and/or recreational cannabis programs in place have experienced decreases in the number of opioid overdoses. The post Consumers Are Replacing Pharmaceuticals With Medical Marijuana appeared first on The Fresh Toast. Cannabis Medical Marijuana News opioids pharmaceuticals

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prohibition Partners (UK) Publish “The Pharmaceutical Cannabis Report”

Cannabis Law Report

Here’s a quick blurb……… The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of … Read More.

February 4 2021: Jazz Pharmaceuticals buys GW Pharma for $7.2 billion

Cannabis Law Report

The post February 4 2021: Jazz Pharmaceuticals buys GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV

February 4 2021: Jim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 billion

Cannabis Law Report

The post February 4 2021: Jim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV

MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics

Cannabis Law Report

The post MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics first appeared on Cannabis Law Report.

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Cannabis Law Report

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. It is important that the pharmaceutical industry continues to work with the medical advisory body to ensure that drugs are cost effective and that its long-term effects are clear.” About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.

Clever Leaves Successfully Delivers First Shipment of EU GMP certified Cannabis derived Pharmaceuticals from Colombia to Germany

Cannabis Law Report

Clever Leaves expands global capabilities and development of market specific pharmaceutical products. The post Clever Leaves Successfully Delivers First Shipment of EU GMP certified Cannabis derived Pharmaceuticals from Colombia to Germany first appeared on Cannabis Law Report.

GW Pharmaceuticals loses $8 million over last quarter

Cannabis Law Report

GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More. Breaking News

What the black market means for cannabis patents

Cannabis Life Network

1) We were curious if there is any weight to Canopy’s new infringement allegations against GW Pharmaceuticals (GWPH). A patent for CO2 extraction of cannabis has been acquired by Canopy Growth Corporation (TSX:WEED), but will small cannabis companies become potential targets? (1)

Pure Jamaican’s Pharma Division Seven10 Nears Start of Exportation of Pharmaceutical Cannabis Ingredients to Mexico With Mexican Senate’s Approval of Cannabis Legislation

Cannabis Law Report

3, 2020 /PRNewswire/ — Pure Jamaican Limited , provider of pharmaceutical cannabinoids, genetics and consumer packaged goods products in large volumes for … Read More. MIAMI , Dec.

Canada: Mydecine signs agreement with Applied Pharmaceutical Innovation (API) at the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences

Cannabis Law Report

The mycology-focused company has signed an agreement with Applied Pharmaceutical Innovation (API), … Read More. Mydecine ( MYCO.CN ) ( NLBIF ) is quickly upping its fungi authority. Psy Business & Law News Partnered With CFN

Europe Cannabis and Pain Management Devices on Cancer Pain Market – Major Technology Giants in Buzz Again | Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics

Cannabis Law Report

Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. Some of the players covered in the study are Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics, Axim Biotechnologies, Medical Marijuana, Zynerba, Pain Management Device Players:, Boston Scientific Crop.,

European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs

Cannabis Law Report

The post European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs first appeared on Cannabis Law Report. Download as PDF October 05, 2020 A milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large … Read More. Press Release EU ZA

And that’s the problem with the Australian cannabis sector – the dominant male mindset & culture ……. “Cann Group COO: ‘we need to put our “big boy pants on” and adopt a pharmaceutical mindset’

Cannabis Law Report

Cann Group COO: ‘we need to put our “big boy pants on” and adopt a pharmaceutical mindset’ first appeared on Cannabis Law Report. Actually there’s two things in that headline that illustrate why Australia has a long way to go That it is… Read More.

Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers

Cannabis Life Network

8, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced […]. The post Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

New data shows Cannabis replacing Alcohol and Pharmaceuticals in the U.S.

Leaf Science

study shows that more and more people are giving up alcohol and pharmaceuticals in favour of cannabis use. are moving away from alcohol and pharmaceuticals in favour of cannabis use. Taking cannabis user archetypes beyond the traditional medical/recreational binary, the study developed nine distinct cannabis consumer profiles and looked at their use of alcohol, pharmaceuticals and cannabis to gain greater insight into the full spectrum of consumer values, lifestyles and behaviours.

Benchmark Signs A Strategic Cooperation With China-Based Zejiang Yatai Pharmaceutical

Canna Newswire

To create, develop and market a variety of high content cannabinoid based pharmaceuticals, natural health products and cosmetics for international markets. CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a non-binding letter of intent of strategic cooperation with China-based Zhejiang Yatai Pharmaceutical Co.,

EU Licensed European Pharmaceutical Company, Freia Farmaceutici Srl

Cannabis Law Report

TSXV: LG and OTC-QB: LGGCF) (“ LGC ”) is pleased to announce that it has paid the 2 nd Tranche, as contractually agreed, in acquiring an equity interest in the Italian pharmaceutical company, Freia Farmaceutici Srl (“Freia”). It should be noted that Freia’s products are currently authorized under the framework of pharmaceutical law and not subject to the evolving, provisional regulation of cannabis. This EU pharmaceutical entity is an optimal addition to LGC.

Benchmark Signs Definitive Investment Cooperation Agreement with China-Based Zhejiang Yatai Pharmaceutical

Canna Newswire

CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. About Zhejiang Yatai Pharmaceutical Co.,

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol. on the new pharmaceutical, and that the vast majority of these side effects are not from any extract of Cannabis, including CBD. Why would a pharmaceutical company do this?

International Cannabis to Supply New Zealand’s NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products

Cannabis Law Report

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. ICC International Cannabis Corp. CSE: WRLD.U)(FWB:

International Cannabis to Supply New Zealand’s NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products

Cannabis Law Report

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry.

GW Pharma to sell for $7.2 Billion, $GWPH jumps for $JAZZ

Cannabis Life Network

Jazz Pharmaceuticals finalized a deal with GW Pharmaceuticals, one of the first and largest producers of legal cannabis-based medicines. GW Pharma ($GWPH) stock jumped nearly 50% after they agreed to sell to Jazz for a landslide of $7.2 billion.

Canopy Growth Corporation patented cannabis extraction infringed, CGC v. GWPH

Cannabis Life Network

Canopy Growth Corporation acquired a patented cannabis extraction technique that GW Pharmaceuticals allegedly infringed. Greenwich Biosciences is a US subsidiary of GW Pharmaceuticals […].

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. Enquiries: GW Pharmaceuticals plc.

Cannabis Wire Investigates Lobbying Power Of “Greenwich Biosciences” The US Arm of GW Pharmaceuticals

Cannabis Law Report

The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states. Greenwich Biosciences , the United States subsidiary of the British GW Pharmaceuticals , registered to lobby in every single state in the country—including ones where all forms of cannabis are prohibited—over the last three years. The Incredibly Large Lobbying Footprint of Greenwich Biosciences.

Breaking the stigma: Psychedelic Drugs

Cannabis Life Network

There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine).

Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc

Cannabis Law Report

According to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to distribute its GMP products to pharma customers, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel. Forbes report.

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).

Canadian Company Signs “Definitive Agreement” With China-based Zhejiang Yatai Pharmaceutical Co., Ltd

Cannabis Law Report

CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. Here’s the press release.

GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug

Cannabis Law Report

Here’s their press release: … Read More. Mark Taylor UK / EU Cannabis Compliance Blog

Press Release: Cabot Wealth Management Upped Gw Pharmaceuticals Plc (GWPH) Stake by $914,524; Share Price Declined; Unitedhealth Group (UNH) Holder New England Investment & Retirement Group Has Raised Stake

Cannabis Law Report

Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. Cabot Wealth Management Inc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $4.15B market cap company.

UK Opinion Piece: The Pharmaceutical Journal – The bar must not be lowered for medical cannabis

Cannabis Law Report

There have been calls to loosen regulations around medical cannabis to increase access for those who need it, but the government must resist and view cannabis with the same scrutiny as any other new medicine. Read all at ( paywall) [link]. Medical Cannabis News

DEA loosens rules on prescription CBD drug Epidiolex

Leafly

Health Politics cannabidiol cbd Epidiolex GW Pharma GW PharmaceuticalsPrescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly.

DEA 66

Thailand: Press Release Thailand Govt Pharma Organization “Pharmaceutical Organization, Department of Medical Cooperation, Research on Medical Marijuana Extracts For cancer patients with neurodegenerative epilepsy And nervous pain”

Cannabis Law Report

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Dr. Sophon Mektana, Advisor to the Minister of Public Health And the Chairman of the Pharmaceutical Organization Committee.